Groundbreaking Vaccine Approval for Meningococcal Group C Disease

Strategic Insights -

American Home Products Corporation, a world leader in research-based pharmaceutical and healthcare products, has received marketing approval from the UK Medicines Control Agency for the first conjugate vaccine against meningococcal Group C disease. This new vaccine, Meningitec(tm), will provide protection against meningococcal C meningitis, a life-threatening disease that causes inflammation of the brain and spinal cord membranes. The UK Department of Health will implement a national immunization program starting November 1999, targeting the most vulnerable group: children under five years of age. Meningococcal meningitis is a leading cause of death in children and young adults up to 20 years old.

Key Takeaways:

  • American Home Products has received marketing approval from the UK Medicines Control Agency for Meningitec(tm), the first conjugate vaccine against meningococcal Group C disease.
  • The vaccine targets meningococcal C meningitis, a life-threatening disease that causes inflammation of the brain and spinal cord membranes.
  • The vaccine provides protection for children under five years of age, the most vulnerable group for developing meningococcal meningitis.
  • The UK Department of Health will implement a national immunization program with Meningitec(tm) starting in November 1999.
  • Bernard Poussot, President of Wyeth-Ayerst Pharmaceuticals, praised the new vaccine as an important advance in the fight against meningitis.
  • Wyeth-Ayerst Laboratories conducted extensive studies, including trials with the Public Health Laboratory Service in the UK and a large-scale study in Northern California Kaiser Permanente.
  • American Home Products is one of the world's largest research-based pharmaceutical and healthcare products companies, with leading products in women's healthcare, cardiovascular disease therapies, central nervous system drugs, and vaccines.
  • The company's press release also notes the forward-looking statements involved in human pharmaceutical research and development, highlighting the inherent risks and uncertainties.

Statistics:

  • 1.4 million people worldwide die from meningococcal disease each year, with 70% of cases occurring in Africa (Source: World Health Organization).
  • Meningococcal meningitis is a leading cause of death in children and young adults up to 20 years old, with a mortality rate of approximately 10% (Source: Centers for Disease Control and Prevention).
  • Meningococcal Group C meningitis is a significant cause of hospital admissions and deaths in the UK, with around 100 cases reported annually (Source: UK Public Health Laboratory Service).
  • Children under five years of age are the most vulnerable to meningococcal meningitis, accounting for 50% of reported cases in the UK (Source: UK Department of Health).

Sources:

  • American Home Products Corporation (NYSE: AHP) press release, dated October 21.
  • UK Medicines Control Agency.
  • World Health Organization (WHO).
  • Centers for Disease Control and Prevention (CDC).
  • UK Public Health Laboratory Service.
  • UK Department of Health.